North America Antimicrobial Susceptibility Testing Market Analysis and Forecast (2020-2035)
The North America antimicrobial susceptibility testing (AST) market is set for robust growth through 2035, driven by increasing antimicrobial resistance, advanced diagnostic technologies, and regulatory initiatives supporting rapid AST adoption. The market comprises diverse testing methods such as disk diffusion, automated AST, and molecular testing, with clinical diagnostics and drug discovery as key application areas. The sector is highly competitive with major companies focusing on innovation, partnerships, and regional expansion to enhance their market presence.
Latest Market Dynamics
Key Drivers
- Rising prevalence of antimicrobial-resistant infections is propelling the demand for advanced and rapid AST solutions across North America. For instance, in June 2024, bioMérieux SA launched a next-gen rapid AST system enabling faster clinical decision-making in major US hospitals.
- Technological advancements, including automation, AI-driven analysis, and molecular diagnostic methods, are transforming the market landscape. In July 2024, Thermo Fisher Scientific Inc. introduced its latest automated susceptibility testing platform with integrated AI analytics to improve result accuracy.
Key Trends
- Accelerated digitalization and adoption of automated AST platforms are streamlining laboratory workflows, reducing turnaround times. BD (Becton, Dickinson and Company) announced its expanded portfolio of automated AST solutions in August 2024, emphasizing rapid result generation.
- Integration of molecular testing with conventional AST methods is gaining momentum, driven by rising demand for comprehensive, rapid diagnostics. Danaher Corporation enhanced its Genotypic Methods offering in September 2024 through acquisition of a leading molecular diagnostics startup.
Key Opportunities
- Expanding use of AST in environmental monitoring and veterinary applications is opening new avenues for market players. In June 2024, Merck KGaA partnered with US-based environmental labs to deploy AST solutions for water safety monitoring.
- Growing investments in public-private partnerships and research funding are fueling new product developments in AST. In August 2024, Accelerate Diagnostics, Inc. secured federal funding aimed at developing next-generation rapid AST technology platforms.
Key Challenges
- High costs associated with adoption of automated and molecular AST technologies present a challenge for smaller labs and facilities. Creative Diagnostics addressed this by launching a cost-effective semi-automated AST system in July 2024.
- Stringent regulatory requirements and complex approval processes for new AST devices continue to slow market entry. Bio-Rad Laboratories, Inc. faced delayed product clearance for its novel AST system, impacting its 2024 rollout strategy.
Key Restraints
- Limited awareness and lack of trained professionals for advanced AST techniques, particularly in rural and small healthcare settings. Sekisui Diagnostics initiated a training program in August 2024 to mitigate this barrier.
- Potential for diagnostic errors and inconsistent test outcomes due to variability in manual AST testing methods. Liofilchem Srl is addressing this by offering standardized, high-reproducibility AST consumables since June 2024.
North America Antimicrobial Susceptibility Testing Market Share by Type, 2025
In 2025, disk diffusion remains the most utilized AST type, followed by rapid automated solutions and broth dilution. Disk diffusion’s widespread adoption is attributed to cost-effectiveness and established use in clinical laboratories. However, rapid automated AST is experiencing the fastest growth, fueled by the need for efficient and scalable testing in hospital settings. Broth dilution and genotypic methods are gaining traction for their precision and ability to provide detailed susceptibility profiles, especially for complex pathogens.
North America Antimicrobial Susceptibility Testing Market Share by Applications, 2025
Clinical diagnostics accounts for the dominant share in AST applications in North America (2025), followed by drug discovery & development and epidemiology. The region’s high incidence of hospital-acquired infections and strong emphasis on infection control drive usage in clinical diagnostics. Drug discovery leverages AST for new compound screening, while epidemiological applications are growing due to heightened public health surveillance and tracking of resistance patterns. Additional expansion is seen in veterinary and environmental testing, reflecting the broader impact of antimicrobial resistance.
North America Antimicrobial Susceptibility Testing Market Revenue (USD Million), 2020-2035
The North America AST market registered a revenue of 1,038 million USD in 2025, projected to climb steadily through 2035. Rising investments in healthcare infrastructure, emphasis on rapid diagnostics, and regulatory mandates for AST in infection control protocols are contributing to sustained market growth. Forecasts indicate continued double-digit CAGR, with market value expected to surpass 2,800 million USD by 2035 as modernization and adoption of automated and molecular testing platforms accelerate across healthcare and allied segments.
North America Antimicrobial Susceptibility Testing Market Year-on-Year Growth (%), 2020-2035
Year-over-year growth in the North America AST market remains robust through 2035, peaking at 7.5% in 2025. Growth rates reflect surges in adoption of digital and AI-driven testing platforms, strengthened pandemic preparedness measures, and ongoing investments in laboratory capabilities. While YOY percentage growth moderates slightly post-2030 as the market matures, strong adoption trends persist due to regulatory requirements and innovation cycles.
North America Antimicrobial Susceptibility Testing Market by Region Share (%), 2025
In 2025, the United States dominates the North America AST market with a 66% share, propelled by its advanced healthcare infrastructure, stringent clinical guidelines, and leadership in diagnostic innovation. Canada follows at 21%, leveraging robust research networks and public health focus, while Mexico’s 13% share is characterized by growing investments in hospital modernization and infectious disease management. Collectively, North America epitomizes a high adoption environment for AST technologies.
North America Antimicrobial Susceptibility Testing Market Players Share (%), 2025
bioMérieux SA holds the leading share of the North America AST market at 19% in 2025, followed by BD (Becton, Dickinson and Company) at 17% and Thermo Fisher Scientific Inc. at 14%. Other prominent players such as Danaher Corporation and Bruker Corporation command significant shares due to robust product portfolios and aggressive R&D. Intense competition and continuous innovation characterize the player landscape, with collaborative ventures and mergers shaping market trajectories. North America Antimicrobial Susceptibility Testing Market Buyers Share (%), 2025
Hospitals and clinical laboratories account for the largest share of AST market buyers at 57% in 2025, highlighting their central role in patient management and infection control. Pharmaceutical & biotechnology firms hold a 20% share, utilizing AST in drug discovery pipelines. Public health agencies, veterinary clinics, and environmental labs represent the remainder, reflecting diversification of market demand driven by the fight against antimicrobial resistance.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 1038 |
| Regions | United States, Canada, Mexico |
| Segments | By Type (Disk Diffusion, Rapid Automated AST, E-test, Broth Dilution, Agar Dilution, Genotypic Methods), By Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology, Veterinary Applications, Environmental Monitoring, Others), By Distribution Channels (Direct Tender, Retail Sales, Online Sales, Distributors/Wholesalers, Group Purchasing Organizations, Others), By Technology (Molecular Testing, Automated AST, Manual Testing, Spectroscopy-based, Microarrays, Others), By Organization Size (Small, Medium, Large) |
| Players | bioMérieux SA, Becton Dickinson and Company (BD), Thermo Fisher Scientific Inc., Danaher Corporation, Bruker Corporation, Creative Diagnostics, Bio-Rad Laboratories Inc., Accelerate Diagnostics Inc., Hardy Diagnostics, Sekisui Diagnostics, Liofilchem Srl, Merck KGaA, ELITechGroup, HiMedia Laboratories Pvt. Ltd., Vela Diagnostics |
Key Recent Developments
- June 2024 – bioMérieux SA launches VITEK AST Gen3 platform for ultra-rapid automated bacterial identification and susceptibility profiling in US hospitals.
- July 2024 – Thermo Fisher Scientific Inc. unveils cloud-integrated, AI-enabled AST solution enabling remote clinical decision support.
- August 2024 – BD introduces Presto AST Full Automation Module, cutting lab workflow times by 30% in flagship diagnostic centers.
- August 2024 – Accelerate Diagnostics, Inc. secures US$37 million federal grant for next-generation rapid AST development.
- September 2024 – Danaher Corporation acquires PathoMole, strengthening its molecular and genotypic AST technology pipeline.
